By: Leslie Lopez According to CNN, Eli Lilly and a company's experimental drug can slow down Alzheimer’s. Their study trial consists of 257 patients with symptoms of early Alzheimer’s. Half of the participants received a placebo while the others received donanimhaber. When the donanimhaber is compared to the placebo it shows that the donanimhaber slowed the cognition and daily function in Alzheimer’s after 76 weeks by 32%. Over 18 months the 32% showed a great impact in Alzheimer’s patients by slowing it down. In the six more months that the patients received from the donanemab they had better memory and the ability to perform daily tasks. According to Maria Carillio phase 2 results are looking great even though it’s early in the trial. The trial has a possibility in slowing and maybe even stopping the progression of Alzheimer’s. When the trial hit 52 weeks it showed that 60% of participants had the levels of a healthy person. After these results the patients were taken off the donanimhaber and placed on the placebo. When cleared from the drugs, the slowing of Alzheimer’s still continued. Carrillo says that this trial is unique because before it started they were focused on both the tau and amyloid beta plaque. The trial is trying to show that if you slow down tau and stop amyloid early in the stage that Alzheimer’s can be slowed down. For the donanimhaber they still need more trials to check if it is a safe and effective enough drug.
0 Comments
Your comment will be posted after it is approved.
Leave a Reply. |
StaffLearn more about the people behind the stories by clicking the button below. Archives
October 2023
Categories |